Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

Clinical Therapeutics

Volumn 25, Issue 2, 2003, Pages 396-421

  McCoy, Christopher ^a,b   Matthews, Samuel James ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clinical pharmacology; Drotrecogin alfa; Protein C; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BRADYKININ; D DIMER; DELTIBANT; DROTRECOGIN; GENTAMICIN; GINKGOLIDE B; HEPARIN; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 4; INTERLEUKIN 6; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTHROMBIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG; WARFARIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GRAM POSITIVE BACTERIUM; HEALTH CARE COST; HEMATEMESIS; HEMATOMA; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; HYPOTENSION; INCIDENCE; MEDICAL LITERATURE; MEDLINE; MENINGOCOCCEMIA; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; RASH; RISK FACTOR; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS AGALACTIAE; TREATMENT OUTCOME;

EID: 0037291655     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80086-3     Document Type: Article

References (83)

1. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med. 1997;25:1095-1100.
2. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002;34:1084-1093.
3. Lynn WA, Cohen J. Adjunctive therapy for septic shock: A review of experimental approaches. Clin Infect Dis. 1995;20:143-158.
4. Abraham E, Anzueto A, Gutierrez G, et al, for the NORASEPT II Study Group. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351:929-933.
5. Opal SM, Fisher CJ Jr, Dhainaut JF, et al, for the Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115-1124.
6. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA. 2001;286:1869-1878.
7. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 1994;22:1720-1728.
8. Dhainaut JF, Tenaillon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med. 1998;26:1963-1971.
9. Fein AM, Bernard GR, Criner GJ, et al, for the CP-0127 SIRS and Sepsis Study Group. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. JAMA. 1997;277:482-487.
10. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
11. US Food and Drug Administration. Product approval information - licensing action. Available at: http://www.fda.gov/cber/products/droteli112101.htm Accessed September 16, 2002.
12. Balk RA. Severe sepsis and septic shock. Definitions, epidemiology and clinical manifestations. Crit Care Clin. 2000;16:179-192.
13. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-1310.
14. Sands KE, Bates DW, Lanken PN, et al, for the Academic Medical Center Consortium Sepsis Project Working Group. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997;278:234-240.
15. Linde-Zwirble W, Angus D, Carcillo J, et al. Age-specific incidence and outcome of sepsis in the US. Crit Care Med. 1999;27(Suppl):33A.
16. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med. 1998;26:2078-2086.
17. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-1655.
18. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
19. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-123.
20. Wenzel RP, Pinsky MR, Ulevitch RJ, Young L. Current understanding of sepsis. Clin Infect Dis. 1996;22:407-413.
21. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;340:207-214.
22. Hellerqvist CG, Rojas J, Green RS, et al. Studies on group B β-hemolytic Streptococcus. I. Isolation and partial characterization of an extracellular toxin. Pediatr Res. 1981;15:892-898.
23. Sundell HW, Yan H, Carter CE, et al. Isolation and identification of the group B streptococcal toxin CM101 from infants with sepsis. J Pediatr. 2000;137:338-344.
24. Bone RC, Grodzin CJ, Balk RA. Sepsis: A new hypothesis for pathogenesis of the disease process. Chest. 1997;112:235-243.
25. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471-1477.
26. Damas P, Canivet J, de Groote D, et al. Sepsis and serum cytokine concentrations. Crit Care Med. 1997;25:405-412.
27. van Deventer SJ, Buller HR, ten Cate JW, et al. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990;76:2520-2526.
28. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997;27:3-9.
29. Hack CE, Zeerleder S. The endothelium in sepsis: Source of and a target for inflammation. Crit Care Med. 2001;29(Suppl):S21-S27.
30. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24:33-44.
31. Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993;103:1536-1542.
32. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320:1165-1172.
33. Sakata Y, Loskutoff DJ, Gladson CL, et al. Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor. Blood. 1986;68:1218-1223.
34. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112(Suppl):321S-329S.
35. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408-416.
36. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood. 1985;66:59-63.
37. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
38. Levi M, ten Cate H, van der Poll T, van Deventer SJ. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA. 1993;270:975-979.
39. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586-592.
40. Cobb JP, Danner RL. Nitric oxide and septic shock. JAMA. 1996;275:1192-1196.
41. Knaus WA, Draper EA, Wagner DE Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13:818-829.
42. Pittet D, Thievent B, Wenzel RP, et al. Bedside prediction of mortality from bacteremic sepsis: A dynamic analysis of ICU patients. Am J Respir Crit Care Med. 1996;153:684-693.
43. Nouira S, Belghith M, Elatrous S, et al. Predictive value of severity scoring systems: Comparison of four models in Tunisian adult intensive care units. Crit Care Med. 1998;26:852-859.
44. National Institutes of Health. Sepsis Clinical Trials Listing. Available at: http://www.clinicaltrials.gov. Accessed December 2, 2002.
45. Yah SB, Chao YB, van Halbeek H. Novel Asn-linked oligosaccharides terminating in GalNAc beta (1→4) [Fuc alpha (1→3)], GlcNAc beta (1→.) are present in recombinant human protein C expressed in human kidney 293 cells. Glycobiology. 1993;3:597-608.
46. Esmon CT, Gu JM, Xu J, et al. Regulation and functions of the protein C anticoagulant pathway. Haematologica. 1999;84:363-368
47. Xigris [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2002.
48. Drag Topics Red Book. Montvale, NJ: Medical Economics Company; 2002.
49. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743-4746.
50. Dhainaut JF, Yah SB, Cariou A, Mira JP. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med. 2002;30(Suppl):S318-S324.
51. Grey ST, Tsuchida A, Hau H, et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-γ, or phorbol ester. J Immunol. 1994;153:3664-3672.
52. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics. 1993;91:418-422.
53. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol. 1996;156:2256-2263.
54. Schmidt-Supprian M, Murphy C, White B, et al. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur Cytokine Netw. 2000;11:407-413.
55. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB. Crit Care Med. 2002;30(Suppl):S288-S293.
56. van Hinsbergh VW, Bertina RM, van Wijngaarden A, et al. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood. 1985;65:444-451.
57. Scully MF, Toh CH, Hoogendoorn H, et al. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost. 1993;69:448-453.
58. Okajima K, Koga S, Kaji M, et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost. 1990;63:48-53.
59. Howey DC, Hartman DL. Preparation for trials of recombinant activated protein C in sepsis: A pharmacokinetic and dynamic study in healthy men and women. Chest. 1997;112(Suppl 3):89. Abstract.
60. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 2001;29:2051-2059.
61. Dhainaut JF, Vincent JL, Yan SB, Bernard GR. Attenuation of sepsis induced coagulation and inflammation by recombinant human activated protein C. Am J Respir Crit Care Med. 2001;163:A554. Abstract.
62. Hirose K, Okajima K, Taoka Y, et al. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg. 2000;232:272-280.
63. Taylor FB Jr, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987;79:918-925.
64. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87:642-647.
65. Shibata M, Kumar SR, Amar A, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. 2001;103:1799-1805.
66. Rintala E, Seppala OP, Kotilainen P, et al. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med. 1998;26:965-968.
67. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126:646-652.
68. Smith OP, White B, Vaughan D, et al. Use of protein C concentrate, heparin, and haemofiltration in meningococcus-induced purpura fulminans. Lancet. 1997;350:1590-1593.
69. White B, Livingstone W, Murphy C, et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000;96:3719-3724.
70. Wcisel G, Joyce D, Gudmundsdottir A, Shasby DM. Human recombinant activated protein C in meningococcal sepsis. Chest. 2002;121:292-295.
71. US Food and Drug Administration Clinical Review: Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] BLA #125029/0. Available at: http://www.fda.gov/cber/products/droteli112101.htm. Accessed September 26, 2002.
72. Ely EW, LaRosa SP, Helterbrand J, Bernard GR. Effect of age on mortality reduction associated with recombinant human activated protein C in patients with severe sepsis. Am J Respir Crit Care Med. 2001;163:A459. Abstract.
73. Angus DC, Vincent JL, Artigas A, et al. The effect of recombinant human activated protein C (rhAPC) on organ dysfunction and functional recovery in severe sepsis. Crit Care Med. 2000;28(Suppl). Abstract 69.
74. Vincent JL, Moreno R, Takala J, et al, for the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707-710.
75. Matthay MA. Severe sepsis - a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med. 2001;344:759-762. Editorial.
76. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347:1027-1030. Editorial.
77. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med. 2002;347:1030-1034. Editorial.
78. Clermont G, Linde-Zwirble WT, Van Hour BA, et al. The effect of recombinant human activated protein C on hospital costs and resource use in severe sepsis. Am J Respir Crit Care Med. 2001;163:A802. Abstract.
79. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost effectiveness of drotrecogin alfa activated (Xigris) in severe sepsis. Crit Care Med. 2002;30:492. Abstract.
80. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347:993-1000.
81. US Centers for Medicare and Medicaid Services. Medicare Program: Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2003 Rates. Fed Regist. 2002;67:49,982-50,017.
82. Applebaum S, Carter C, Chuen T, et al. Patient selection guidelines and DUE for drotrecogin alfa (activated). Hosp Formul. 2002;37(Suppl 1):3-15.
83. Vanscoy G, Devlin J, Ponzillo J, Kuhl DA. Implementing guidelines for drotrecogin alfa (activated): Three perspectives. P & T. 2002;27(Suppl):2-13.